F. Eisinger

J. Morère, F. Eisinger, J. Viguier, 2011, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

Novel indications for BRCA1 screening using individual clinical and morphological features

D. Birnbaum, J. Peyrat, R. Lidereau, 1999, International journal of cancer.

Breast cancer screening in France: results of the EDIFICE survey

M. Namer, X. Pivot, S. Dolbeault, 2008, International journal of medical sciences.

IMPACT OF GENE PATENTS ON THE COST-EFFECTIVE DELIVERY OF CARE: THE CASE OF BRCA1 GENETIC TESTING

D. Stoppa-Lyonnet, J. Moatti, H. Sobol, 2003, International Journal of Technology Assessment in Health Care.

Testing for BRCA1 mutations: a cost-effectiveness analysis

D. Stoppa-Lyonnet, J. Moatti, H. Sobol, 2002, European Journal of Human Genetics.

Impact of organised programs on colorectal cancer screening

J. Blay, M. Namer, X. Pivot, 2008, BMC Cancer.

Cancer screening in France: subjects’ and physicians’ attitudes

J. Blay, M. Namer, X. Pivot, 2007, Cancer Causes & Control.

Comparison of physicians' and cancer prone women's attitudes about breast/ovarian prophylactic surgery. Results from two national surveys

D. Stoppa-Lyonnet, J. Moatti, H. Sobol, 2004, Familial Cancer.

Evidence-Based Public HealthRegular screening of young women with BRCA1/2 genes can detect breast cancers

H. Sobol, F. Eisinger, 2002 .

Breast cancer surveillance is less effective for high risk women

H. Sobol, F. Eisinger, 2001 .

Re: Biologic characteristics of interval and screen-detected breast cancers.

H. Sobol, F. Eisinger, C. Juliain-Reynier, 2000, Journal of the National Cancer Institute.

Disclosure to the family of breast/ovarian cancer genetic test results: patient's willingness and associated factors.

D. Stoppa-Lyonnet, H. Sobol, C. Lasset, 2000, American journal of medical genetics.

Management of women at high genetic risk of ovarian cancer

W. Burke, H. Sobol, F. Eisinger, 1999, The Lancet.

Information-Seeking Behaviour and Psycho-Social Interactions during the Genetic Testing Process

A. Mogoutov, H. Sobol, C. Julian‐Reynier, 2004, Public Health Genomics.

Four Years Analysis of Cancer Genetic Clinics Activity in France from 1994 to 1997: A Survey on 801 Patients

D. Stoppa-Lyonnet, Y. Bignon, H. Sobol, 2002, Disease markers.

Distinct and complementary information provided by use of tissue and DNA microarrays in the study of breast tumor markers.

F. Bertucci, C. Nguyen, D. Birnbaum, 2002, The American journal of pathology.

Five genetic variants associated with prostate cancer.

F. Eisinger, 2008, The New England journal of medicine.

Ovarian cancer patients at high risk of BRCA mutation: the constitutional genetic characterization does not change prognosis

P. Viens, H. Sobol, C. Popovici, 2016, Familial Cancer.

Screening for prostate cancer: growth without control

J. Blay, X. Pivot, J. Morère, 2011, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

Phenocopies: actual risk or self-fulfilling prophecy?

F. Eisinger, 2007, Journal of medical genetics.

Prostate cancer screening: contrasting trends

X. Pivot, J. Blay, C. Touboul, 2015, Cancer Causes & Control.

Colon Cancer Screening Programs: Impact of an Organized Screening Strategy Assessed by the EDIFICE Surveys

S. Couraud, J. Morère, F. Eisinger, 2018, Current Oncology Reports.

Increasing Coverage Rates for Mammographic Screening in France in Older Women––16 Years of Follow‐Up

J. Blay, X. Pivot, F. Beck, 2011, The breast journal.

Sociogeographical factors associated with participation in colorectal cancer screening.

A. Loundou, P. Auquier, J. Seitz, 2010, Gastroenterologie clinique et biologique.

Organized colorectal cancer screening programmes: how to optimize efficiency among general practitioners

X. Pivot, F. Eisinger, J. Viguier, 2011, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers

W. Chung, J. Benítez, R. Eeles, 2020, Breast Cancer Research.

Breast cancer screening in women aged 50–74 years: isthereroom for improvement?

J. Blay, X. Pivot, J. Morère, 2011, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

Prevention and screening

S. Duffy, A. Carrato, M. Kusumoto, 2012 .

Acceptable strategies for dealing with hereditary breast/ovarian cancer risk.

J. Moatti, H. Sobol, F. Eisinger, 1997, Journal of the National Cancer Institute.

Highly favorable outcome in BRCA-mutated metastatic breast cancer patients receiving high-dose chemotherapy and autologous hematopoietic stem cell transplantation

F. Bertucci, P. Viens, C. Tarpin, 2016, Bone Marrow Transplantation.

Re: Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers.

L. Huiart, F. Eisinger, 2009, Journal of the National Cancer Institute.

Front & Back Matter

D. Weisenburger, H. Watari, N. Sakuragi, 2013, Pathobiology.

Variation in prophylactic surgery decisions

W. Foulkes, H. Sobol, C. Julian‐Reynier, 2000, The Lancet.

[Breast cancer screening for women with a strong familial risk].

F. Eisinger, 2005, Bulletin du cancer.

Cancer de l’endomètre du syndrome HNPCC

S. Olschwang, A. Bats, F. Lécuru, 2008 .

[Endometrial cancer in HNPCC syndrome].

P. Laurent-Puig, S. Olschwang, A. Bats, 2008, Journal de gynecologie, obstetrique et biologie de la reproduction.

CYP2D6 and Ockham's razor.

F. Eisinger, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

More about: multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations.

D. Birnbaum, H. Sobol, E. Charafe-Jauffret, 1999, Journal of the National Cancer Institute.

Truncation at conserved terminal regions of BRCA1 protein is associated with highly proliferating hereditary breast cancers.

D. Birnbaum, J. Peyrat, D. Stoppa-Lyonnet, 1996, Cancer research.

The Impact of Genetic Testing on Healthcare Insurance

J. Moatti, F. Orsi, Michael Hoy, 2003 .

Poly (ADP-Ribose) Polymerase Inhibitors for De Novo BRCA2-Null Small-Cell Prostate Cancer.

F. Bertucci, D. Birnbaum, G. Pignot, 2018, JCO precision oncology.

Genetic Testing for Familial Cancer

F. Eisinger, 2008, Public Health Genomics.

A new hybrid record linkage process to make epidemiological databases interoperable: application to the GEMO and GENEPSO studies involving BRCA1 and BRCA2 mutation carriers

F. Révillion, Chloé-Agathe Azencott, N. Sevenet, 2020, BMC Medical Research Methodology.

Loss of heterozygosity in human breast carcinomas in the ataxia telangiectasia, Cowden disease and BRCA1 gene regions

D. Birnbaum, C. Eng, C. Theillet, 1997, Oncogene.

Molecular study of CEPBA in familial hematological malignancies

L. Huiart, L. Demange, L. Faivre, 2009, Familial Cancer.

Angelina and Brad effect

F. Eisinger, 2016, Familial Cancer.

Assessing the risk of BRCA1‐associated breast cancer using individual morphological criteria

D. Birnbaum, R. Lidereau, H. Sobol, 2001, Histopathology.

p53 involvement in BRCA1-associated breast cancer

H. Sobol, J. Jacquemier, J. Guinebretière, 1997, The Lancet.

[Identification and management of hereditary predisposition to cancer of the breast and the ovary (update 2004)].

H. Sobol, A. Tardivon, C. Noguès, 2004, Bulletin du cancer.

Evidence for a third breast-cancer susceptibility gene

D. Birnbaum, H. Sobol, F. Eisinger, 1994, The Lancet.

Cancer survivors: familial risk perception and management advice given to their relatives

A. Bouhnik, C. Julian‐Reynier, F. Eisinger, 2011, Familial Cancer.

Histoprognostic grade in BRCA1-associated breast cancer

D. Birnbaum, H. Sobol, J. Jacquemier, 1995, The Lancet.

Ovarian cancer patients at high risk of BRCA mutation: the constitutional genetic characterization does not change prognosis

P. Viens, H. Sobol, C. Popovici, 2016, Familial Cancer.

Re: familial multiple myeloma: a family study and review of the literature.

N. Philip, H. Sobol, N. Vey, 2002, Journal of the National Cancer Institute.

Impact of awareness of cancer among acquaintances on cancer screening attendance

J. Blay, X. Pivot, J. Morère, 2011, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

Cancer Genetics Service Provision: A Comparison of Seven European Centres

G. Rennert, C. V. van Asperen, E. Legius, 2004, Public Health Genomics.

Autism , inflammatory bowel disease , and MMR vaccine

H. Sobol, J. Whorton, D. Serin, 2022 .

Hereditary breast cancer, circa 1750

H. Sobol, J. Whorton, D. Serin, 1998, The Lancet.

Steroid receptors in hereditary breast carcinomas associated with BRCA1 or BRCA2 mutations or unknown susceptibility genes

Daniel Birnbaum, D. Birnbaum, H. Sobol, 1999, Cancer.

BRCA1 and medullary breast cancer.

D. Birnbaum, H. Sobol, C. Noguès, 1998, JAMA.

[Personalized medicine and breast cancer: anticipatory medicine, prognostic evaluation and therapeutic targeting].

F. Bertucci, A. Gonçalves, F. Eisinger, 2013, Bulletin du cancer.

Familial hematological malignancies: ASXL1 gene investigation

L. Faivre, H. Sobol, C. Dugast, 2016, Clinical and Translational Oncology.

Molecular study of the perforin gene in familial hematological malignancies

L. Huiart, L. Demange, L. Faivre, 2011, Hereditary cancer in clinical practice.

Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers.

Dieter Niederacher, Ute Hamann, Alfons Meindl, 2008, American journal of human genetics.

Targeted NGS, array-CGH, and patient-derived tumor xenografts for precision medicine in advanced breast cancer: a single-center prospective study

F. Bertucci, D. Birnbaum, P. Finetti, 2016, Oncotarget.

Diagnostic chest X-rays and breast cancer risk among women with a hereditary predisposition to breast cancer unexplained by a BRCA1 or BRCA2 mutation

D. Stoppa-Lyonnet, S. Mazoyer, F. Damiola, 2021, Breast cancer research : BCR.

Effects of genetic consultation on perception of a family risk of breast/ovarian cancer and determinants of inaccurate perception after the consultation.

D. Stoppa-Lyonnet, L. Huiart, H. Sobol, 2002, Journal of clinical epidemiology.

French Physicians’ Knowledge about Hereditary Breast/Ovarian Cancer: The Need for Continuing Vocational Training in Genetics

J. Moatti, H. Sobol, C. Julian‐Reynier, 2000, Public Health Genomics.

Marker segregation information in breast/ovarian cancer genetic counseling: is it still useful? Groupe Génétique et Cancer de la Fédération Nationale des Centres de Lutte Contre le Cancer.

C. Bonaïti‐pellié, L. Essioux, O. Sinilnikova, 1998, American journal of medical genetics.

Attitudes towards cancer predictive testing and transmission of information to the family.

Y. Bignon, H. Sobol, C. Julian‐Reynier, 1996, Journal of medical genetics.

Oral contraceptive use and ovarian cancer risk for BRCA1/2 mutation carriers: an international cohort study

R. Eeles, J. Hopper, D. Easton, 2021, American journal of obstetrics and gynecology.

Genome-wide search for loss of heterozygosity shows extensive genetic diversity of human breast carcinomas.

D. Birnbaum, H. Sobol, J. Jacquemier, 1997, Cancer research.

Genome‐wide search for loss of heterozygosity in Burkitt lymphoma cell lines

D. Birnbaum, G. Lenoir, H. Sobol, 2002, Genes, chromosomes & cancer.

Gene expression profiles of poor-prognosis primary breast cancer correlate with survival.

E. Devilard, F. Bertucci, B. Loriod, 2002, Human molecular genetics.

Hereditary cancer gene hunting. a phase of declining success?

D. Horsman, F. Eisinger, 2007, Medical hypotheses.

Variation in breast cancer risk associated with factors related to pregnancies according to truncating mutation location, in the French National BRCA1 and BRCA2 mutations carrier cohort (GENEPSO)

R. Lidereau, D. Stoppa-Lyonnet, P. Pujol, 2012, Breast Cancer Research.

Variation in breast cancer risk associated with factors related to pregnancies according to truncating mutation location, in the French National BRCA1/2 carrier cohort (GENEPSO).

R. Lidereau, D. Stoppa-Lyonnet, P. Pujol, 2018 .

Recommendations for medical management of hereditary breast and ovarian cancer: the French National Ad Hoc Committee.

D. Stoppa-Lyonnet, H. Sobol, J. Feingold, 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

GENESIS: a French national resource to study the missing heritability of breast cancer

D. Stoppa-Lyonnet, O. Sinilnikova, S. Mazoyer, 2016, BMC Cancer.

Common variants of the BRCA1 wild-type allele modify the risk of breast cancer in BRCA1 mutation carriers.

F. Couch, T. Rebbeck, J. Benítez, 2011, Human molecular genetics.

[Medical chemoprevention of cancers. From the point of view of social sciences].

J. Moatti, P. Bourret, F. Eisinger, 1995, Bulletin du cancer.

Re: Gene expression profiles of BRCA1-linked, BRCA2-linked, and sporadic ovarian cancers.

Daniel Birnbaum, François Bertucci, F. Bertucci, 2002, Journal of the National Cancer Institute.

Highly favorable outcome in BRCA-mutated metastatic breast cancer patients receiving high-dose chemotherapy and autologous hematopoietic stem cell transplantation

F. Bertucci, P. Viens, C. Tarpin, 2017, Bone Marrow Transplantation.

Typical medullary breast carcinomas have a basal/myoepithelial phenotype

D. Birnbaum, L. Xerri, S. Lakhani, 2005, The Journal of pathology.

Histoprognostic Grade in Hereditary Breast Cancer: Is Inheritance Linked to BRCA1 a Bad Prognostic Factor?

D. Birnbaum, D. Stoppa-Lyonnet, H. Sobol, 1996 .

Telehealth applied to physical activity during cancer treatment: a feasibility, acceptability, and randomized pilot study

F. Cury, T. Marqueste, M. Cappiello, 2018, Supportive Care in Cancer.

Low frequency of lymph-node metastasis in BRCA1-associated breast cancer

D. Birnbaum, H. Sobol, C. Noguès, 1998, The Lancet.

Major improvement in the efficacy of BRCA1 mutation screening using morphoclinical features of breast cancer.

D. Birnbaum, I. Bièche, R. Lidereau, 2000, Cancer research.

GATA2 gene analysis in several forms of hematological malignancies including familial aggregations

L. Faivre, H. Sobol, C. Dugast, 2017, Annals of Hematology.

Full access to medical records does not modify anxiety in cancer patients

P. Viens, D. Coso, G. Gravis, 2011, Cancer.

Decline in Cancer Screening in Vulnerable Populations? Results of the EDIFICE Surveys

S. Couraud, C. Touboul, J. Morère, 2018, Current Oncology Reports.

Impact of an information booklet on satisfaction and decision-making about BRCA genetic testing.

D. Stoppa-Lyonnet, A. Chompret, J. Fricker, 2006, European journal of cancer.

Cancer prone persons. A randomized screening trial based on colonoscopy: background, design and recruitment

J. Faivre, H. Sobol, H. Allemand, 2004, Familial Cancer.

Loss of heterozygosity and linkage analysis in breast carcinoma: indication for a putative third susceptibility gene on the short arm of chromosome 8.

L. Essioux, R. Lidereau, M. Pébusque, 1995, Oncogene.

Cancer screening in France: third edition of the EDIFICE survey

J. Blay, X. Pivot, C. Touboul, 2015, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

Breast cancer screening controversy: too much or not enough?

J. Blay, X. Pivot, C. Touboul, 2015, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

Acceptability of cancer chemoprevention trials: impact of the design

D. Horsman, L. Huiart, H. Sobol, 2008, International journal of medical sciences.

Socioeconomic deprivation is associated with decreased survival in patients with acute myeloid leukemia.

J. Rey, J. Boher, A. Charbonnier, 2020, Cancer epidemiology.

Maintaining professional activity during breast cancer treatment.

N. Dohollou, H. Naman, A. Lortholary, 2016, European journal of cancer care.

Clinical utility gene card for: Lynch syndrome (MLH1, MSH2, MSH6, PMS2, EPCAM) - update 2012

Brigitte Schlegelberger, Sylviane Olschwang, P. Hutter, 2012, European Journal of Human Genetics.

Cancer genetics clinics: target population and consultees' expectations.

Y. Bignon, H. Sobol, C. Julian‐Reynier, 1996, European journal of cancer.

Empirical Validation of the Genetic Psychosocial Risk Instrument – French Version (GPRI-F)

C. Maheu, M. Esplen, C. Julian‐Reynier, 2018, Science of Nursing and Health Practices - Science infirmière et pratiques en santé.

Clinical utility gene card for: Lynch syndrome (MLH1, MSH2, MSH6, PMS2)

Brigitte Schlegelberger, Sylviane Olschwang, P. Hutter, 2010, European Journal of Human Genetics.

Physicians' attitudes towards mammography and prophylactic surgery for hereditary breast/ovarian cancer risk and subsequently published guidelines

J. Moatti, H. Sobol, C. Julian‐Reynier, 2000, European Journal of Human Genetics.

Fallopian tube cancer as a feature of BRCA1-associated syndromes.

D. Birnbaum, H. Sobol, J. Jacquemier, 2000, Gynecologic oncology.

[Identification and management of hereditary breast-ovarian cancers (2004 update)].

H. Sobol, A. Tardivon, C. Noguès, 2004, Pathologie-biologie.

Tamoxifen and breast cancer risk in women harboring a BRCA1 germline mutation: computed efficacy, effectiveness and impact.

D. Birnbaum, H. Sobol, E. Charafe-Jauffret, 2001, International journal of oncology.

Cancer survivors’ efforts to facilitate return to work

M. Lehucher-Michel, F. Eisinger, C. Cypowyj, 2020, Psychology, health & medicine.

Re: Randomized trial of a specialist genetic assessment service for familial breast cancer.

J. Moatti, H. Sobol, C. Julian‐Reynier, 2001, Journal of the National Cancer Institute.

Cancer genetic clinics: why do women who already have cancer attend?

Y. Bignon, H. Sobol, C. Julian‐Reynier, 1998, European journal of cancer.

Lung cancer risks, beliefs and healthcare access among the underprivileged

J. Blay, X. Pivot, C. Touboul, 2015, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

Subjective interpretation of inconclusive BRCA1/2 cancer genetic test results and transmission of information to the relatives

L. Huiart, H. Sobol, C. Julian‐Reynier, 2009, Psycho-oncology.

[INSERM-FNCLCC collective expertise. Recommendations for medical management of women with genetic risk of developing breast and/or ovarian cancer].

D. Stoppa-Lyonnet, H. Sobol, J. Feingold, 1999, Annales de genetique.

Prediction of BRCA1 Germ-Line Mutation Status in Patients with Breast Cancer Using Histoprognosis Grade, MS110, Lys27H3, Vimentin, and KI67

J. Peyrat, R. Lidereau, L. Huiart, 2013, Pathobiology.

Prediction of BRCA 1 GermLine Mutation Status in Patients with Breast Cancer Using Histoprognosis Grade , MS 110 , Lys 27 H 3 , Vimentin , and KI 67

J. Peyrat, R. Lidereau, L. Huiart, 2013 .

Familial hematological malignancies: new IDH2 mutation

A. Paci, V. Penard-Lacronique, L. Faivre, 2016, Annals of Hematology.

Impact of general practitioners' sex and age on systematic recommendation for cancer screening

J. Blay, X. Pivot, J. Morère, 2011, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

Prostate cancer screening: contrasting trends

X. Pivot, J. Blay, C. Touboul, 2015, Cancer Causes & Control.

Beliefs and behavior regarding e-cigarettes in a large cross-sectional survey

J. Blay, X. Pivot, S. Couraud, 2018, Preventive medicine reports.

BRCA1-p53 relationship in hereditary breast cancer.

D. Birnbaum, J. Peyrat, H. Sobol, 1997, International journal of oncology.

Cigarette smoking in women after BRCA1/2 genetic test disclosure: a 5-year follow-up study of the GENEPSO PS cohort

A. Bouhnik, N. Resseguier, C. Lasset, 2014, Genetics in Medicine.

Uptake of breast cancer screening in women aged over 75years: a controversy to come?

J. Blay, X. Pivot, J. Morère, 2011, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

Organized colorectal cancer screening programmes: how to optimize efficiency in the general population

J. Blay, X. Pivot, J. Morère, 2011, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

Cultural basis for differences between US and French clinical recommendations for women at increased risk of breast and ovarian cancer

N. Holtzman, G. Geller, W. Burke, 1999, The Lancet.

Current and Former Smokers: Who Wants To Be Screened?

S. Couraud, A. Cortot, L. Greillier, 2018, Clinical lung cancer.

Perception of Lung Cancer Risk: Impact of Smoking Status and Nicotine Dependence

S. Couraud, A. Cortot, L. Greillier, 2018, Current Oncology Reports.

Histological type and syncytial growth pattern affect E‐cadherin expression in a multifactorial analysis of a combined panel of sporadic and BRCA1‐associated breast cancers

D. Birnbaum, J. Peyrat, R. Lidereau, 1999, International journal of cancer.

From DNA to the Community

Maria do Rosário Silva, A. Kent, D. Gaudet, 2000, Public Health Genomics.

Cancer screening: continuing instability.

F. Eisinger, 2015, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

Social stratification, risk factor prevalence and cancer screening attendance

J. Blay, X. Pivot, C. Touboul, 2015, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

Acceptability of prophylactic mastectomy in cancer-prone women.

D. Stoppa-Lyonnet, H. Sobol, C. Lasset, 2000, JAMA.

ARLTS1, potential candidate gene in familial aggregation of hematological malignancies.

L. Faivre, H. Sobol, C. Dugast, 2017, Bulletin du cancer.

Colorectal cancer screening program: cost effectiveness of systematic recall letters.

Rémi Didelot, J. Seitz, François Eisinger, 2007, Gastroenterologie clinique et biologique.

Factors influencing colorectal cancer screening participation rates in 2016.

J. Blay, X. Pivot, S. Couraud, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Three novel BRCA2 germline mutations (1864 delT, 6132 del4, 8208 del5) detected in breast cancer families identified in the south of France

D. Birnbaum, H. Sobol, R. Sauvan, 2001, Human mutation.

[Synchronous cancers. A case with three localizations: rectal cancer associated with familial polyposis, breast cancer and adrenal gland cancer].

H. Sobol, J. Seitz, G. Monges, 1995, Presse medicale.

[Impact of recent oncogenetic progress on the management of high risk breast cancer patients: the example of BRCA1 and BRCA2 genes].

D. Birnbaum, H. Sobol, R. Sauvan, 1998, Annales d'endocrinologie.

[Pharmaco and diet based prostate cancer prevention].

G. Cancel-Tassin, O. Cussenot, G. Gravis, 2013, Bulletin du cancer.

Full access to medical records does not modify anxiety in cancer patients

P. Viens, D. Coso, G. Gravis, 2011, Cancer.

Melanoma risk‐takers: fathers and sons

X. Pivot, F. Grange, L. Mortier, 2015, Journal of the European Academy of Dermatology and Venereology : JEADV.

The choice of bilateral prophylactic mastectomy.

L. Huiart, H. Sobol, F. Eisinger, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[Cancer screening in France: 10 years of analysis of behaviours by the EDIFICE surveys].

J. Blay, X. Pivot, S. Couraud, 2017, Bulletin du cancer.

Prevention and screening

S. Duffy, A. Carrato, M. Kusumoto, 2012 .